Sells medicines for rare sleep disorders, epilepsy and cancers to patients with those conditions.
10-K for FY2025, filed Feb 24, 2026Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their…View ↗
Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product approved by FDA in July 2020, and launched in the U.S.…View ↗
Our Rare Sleep Products. We are the leader in the development and commercialization of oxybate therapy for patients with rare sleep…View ↗
Our Rare Epilepsy ProductView ↗
Our Rare Oncology ProductsView ↗
Jazz sells medicines to specialty pharmacies, distributors and hospitals, with product sales tied to delivery. It also earns royalties on licensed medicine sales and receives upfront and milestone payments for licensing rights.
10-K for FY2025, filed Feb 24, 2026In the U.S., Xywav and Xyrem are sold to one certified specialty pharmacy, ESSDS, that ships Xywav and Xyrem directly to patients. Also in…View ↗
Product sales revenue is recognized when control has transferred to the customer, which occurs at a point in time, which is typically on…View ↗
In addition, since January 2023, our oxybate products have faced competition from AG high-sodium oxybate pursuant to a settlement agreement…View ↗
We enter into out-licensing agreements under which we license certain rights to our products or product candidates to third parties. If a…View ↗
At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered…View ↗
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by product or service ↗$4.3B
10-K for FY2025, filed Feb 24, 2026
$4.3B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales, net
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
94%
FY2022: 100%
|
Product sales, net, FY2025
$4B Sources
|
Sold outright |
|
High-sodium oxybate AG royalty revenue
Licensed
|
5.0%
FY2022: 0.0%
|
High-sodium oxybate AG royalty revenue, FY2025
$211.7M Sources
|
Licensed |
|
Other royalty and contract revenues
Licensed
|
0.8%
FY2022: 0.5%
|
Other royalty and contract revenues, FY2025
$34M Sources
|
Licensed |
U.S. oxybate and Modeyso prescriptions go through certified specialty pharmacies that ship directly to patients; other medicines are sold to specialty pharmacies, distributors and hospitals. Outside the U.S., sales run through wholesalers and distributors, with some European sales made directly to hospitals and local wholesalers.
10-K for FY2025, filed Feb 24, 2026
10-K for FY2025, filed Feb 24, 2026
Year Ended December 31, 2025 2024 2023 ESSDS 42 % 42 % 48 % ASD 11 % 9 % 7 % McKesson 10 % 12 % 11 %View ↗
Not on paper. It lost $356.1M in FY2025, but brought in more cash than it spent: $1.3B of free cash flow.
10-Q for Q3 FY2026, filed Nov 2, 2026
−$483.4MView ↗
10-Q for Q3 FY2026, filed Nov 2, 2026
Open tableView ↗
8-K, filed Aug 25, 2026
On August 25, 2026, Jazz Pharmaceuticals plc (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration…View ↗
8-K, filed Aug 10, 2026
On August 10, 2026, Jazz Pharmaceuticals, Inc. (“Parent”), a wholly owned subsidiary of Jazz Pharmaceuticals Public Limited Company…View ↗
8-K, filed Aug 3, 2026
Highest ever total quarterly revenues of $1.2 billion with 16% year-over-year (YoY) growth. Generated GAAP / non-GAAP1 adjusted earnings…View ↗
Growing. Revenue grew 38% in 4 years, from $3.1B in FY2021 to $4.3B in FY2025, about 8% a year.
Portfolio additions
Jazz added Ziihera and Modeyso to its commercialized cancer medicines, alongside its earlier treatments for sleep disorders, epilepsy and cancer.
10-K for FY2022, filed Mar 1, 2023
Competes with Alkermes, Avadel, Amneal, Ascent, Hikma, Lupin, Teva, Granules, Harmony Biosciences, Axsome, Takeda, Merck &, Eisai, Centessa Pharmaceuticals, Zogenix, UCB, Marinus Pharmaceuticals, Ovid Therapeutics, Praxis Precision Medicines, and Bright Minds Biosciences
10-K for FY2025, filed Feb 24, 2026Xywav and Xyrem. Xywav and Xyrem are approved by FDA and marketed in the U.S. for the treatment of both cataplexy and EDS in both adult and…View ↗
Loading...